The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung

科学家揭示非小细胞肺癌新的驱动因素与药物靶点- 专区- 生物谷

The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung

医药前沿nature发文：CLIP1-LTK 融合基因-非小细胞肺癌的新治疗靶点

IJMS, Free Full-Text

AMG-510 and cisplatin combination increases antitumor effect in

Recombinant Anti-LTK antibody [EPR5175(2)] (ab129155)

Nature里程碑：非小细胞肺癌新靶点——CLIP1-LTK

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung

EGFR exon 20 insertion mutations and ERBB2 mutations in lung

Identification of Ultrasound-Sensitive Prognostic Markers of LAML

Frontiers Cancer/Testis Antigens as Biomarker and Target for the

Department of Thoracic Oncology National Cancer Center Hospital East

Recombinant Anti-LTK antibody [EPR5175(2)] (ab129155)

Genotype-phenotype mapping of a patient-derived lung cancer

Lung Cancer Program - DF/HCC